CFFP
JAZZ icon

Center for Financial Planning’s Jazz Pharmaceuticals JAZZ Stock Holding History

Center for Financial Planning’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$121 – 608
2024
Q1 		$121 Buy
+1
New +$122 ﹤0.01% 598
2021
Q3 		– Sell
-15
Closed -$3K – 510
2021
Q2 		$3K Buy
+15
New +$2.6K ﹤0.01% 439

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Center for Financial Planning's JAZZ Position: Q2 2024 in Review

Center for Financial Planning sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 1 share — an estimated $121 sold.

Center for Financial Planning first reported a position in JAZZ in Q2 2021 and held it in 2 quarters. The position peaked at $3K in Q2 2021. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • Center for Financial Planning reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Center for Financial Planning sold 1 Jazz Pharmaceuticals share in Q2 2024, an estimated $121.
  • Center for Financial Planning first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Center for Financial Planning's Jazz Pharmaceuticals position peaked at $3K in Q2 2021.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Center for Financial Planning's 13F filing for Q2 2024, filed 18 Jul 2024.